- Orchestra BioMed Announces Further Details on In-Person R&D Day in New York Featuring Key Opinion Leaders to Discuss AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
- Orchestra BioMed to Participate in Jefferies Global Healthcare Conference
- Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update
- Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents
- Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
- Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
- Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
- Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
- Orchestra BioMed to Participate in Upcoming Investor Conferences
- Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients
More ▼
Key statistics
On Friday, Orchestra Biomed Holdings Inc (OBIO:NMQ) closed at 7.98, 89.10% above the 52 week low of 4.22 set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.96 |
---|---|
High | 8.10 |
Low | 7.81 |
Bid | 3.20 |
Offer | 8.74 |
Previous close | 7.99 |
Average volume | 145.57k |
---|---|
Shares outstanding | 35.79m |
Free float | 21.33m |
P/E (TTM) | -- |
Market cap | 282.73m USD |
EPS (TTM) | -1.47 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 21:00 BST.
More ▼